Boehringer Ingelheim Announces Growth in the Bay Area
October 31, 2024
By: Payment Week
FREMONT, Calif., October 31, 2024 – Boehringer Ingelheim Fremont, Inc., the U.S. arm of Boehringer Ingelheim’s Biopharmaceuticals Business, today marked the inauguration of a major site expansion, which will add 75,000 sq. ft. to its local footprint and nearly 300 new jobs to its workforce. The expansion, part of a $217 million investment over several years, is expected to more than double the site’s manufacturing capacity.
To date, Boehringer Ingelheim Fremont has already completed nearly 150,000 contractor hours for planning and construction of the site expansion, and will continue to grow its operations over several years. The highly diverse team in Fremont consists of approximately 500 highly qualified scientists, engineers, operators and specialists, with 100 employees added in the last year as part of the expansion.
“At Boehringer Ingelheim, we are driven to improve the lives of patients through the development and delivery of high-quality innovative treatments,” said Jens Vogel, President, Boehringer Ingelheim Fremont, Inc. “We are an advanced biologics manufacturer and developer for our own products, and for our partner companies. We are proud to have a strong and expanding presence here in the Bay Area, the birthplace of biotech, and excited that we can now help the biotech community bring even more therapies to patients in need.”
Boehringer Ingelheim Fremont focuses on several therapeutic areas, including immunology, oncology and biosimilars for its company pipeline and portfolio. In addition, Fremont is part of Boehringer Ingelheim’s BioXcellence world-leading contract manufacturing business. Last year, the site was awarded $25.5 million in two separate tax credits from the state of California, the largest award to a pharmaceutical company.
About Boehringer Ingelheim
Boehringer Ingelheim Fremont, Inc., based in Fremont, CA, is a human biologics manufacturing facility. With a diverse team of over 500 people, we cover biopharmaceutical development and manufacturing from small scale to commercial, from drug substance manufacturing to fill/finish, packaging and medical device assembly. Everything we do, we do to help patients - through the reliable supply of high quality medicines and being on the cutting edge of technology and innovation.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, Conn., is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. Boehringer Ingelheim is one of the world’s top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 50,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
Boehringer Ingelheim is committed to improving lives and providing valuable services and support to patients and their families. Our employees create and engage in programs that strengthen our communities. Please visit www.boehringer-ingelheim.us/
In 2017, Boehringer Ingelheim achieved net sales of about $20.4 billion (18.1 billion euros). R&D expenditure corresponds to approximately $3.4 billion (three billion euros), or 17.0 percent of its net sales.
For more information please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
